Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
AVDL

AVDL - Avadel Pharmaceuticals PLC Stock Price, Fair Value and News

16.19USD+0.25 (+1.57%)Delayed as of 19 Jul 2024, 03:06 pm ET

Market Summary

AVDL
USD16.19+0.25
Delayedas of 19 Jul 2024, 03:06 pm
1.57%

AVDL Stock Price

View Fullscreen

AVDL RSI Chart

AVDL Valuation

Market Cap

1.5B

Price/Earnings (Trailing)

-9.77

Price/Sales (Trailing)

27.83

EV/EBITDA

-9.85

Price/Free Cashflow

-11.97

AVDL Price/Sales (Trailing)

AVDL Profitability

EBT Margin

-284.61%

Return on Equity

-200.08%

Return on Assets

-93.41%

Free Cashflow Yield

-8.35%

AVDL Fundamentals

AVDL Revenue

Revenue (TTM)

55.0M

Rev. Growth (Yr)

14.0K%

Rev. Growth (Qtr)

40.41%

AVDL Earnings

Earnings (TTM)

-156.8M

Earnings Growth (Yr)

11.18%

Earnings Growth (Qtr)

5.02%

Breaking Down AVDL Revenue

52 Week Range

9.7216.33
(Low)(High)

Last 7 days

-3.1%

Last 30 days

2.1%

Last 90 days

-8.1%

Trailing 12 Months

15.9%

How does AVDL drawdown profile look like?

AVDL Financial Health

Current Ratio

2.85

AVDL Investor Care

Shares Dilution (1Y)

25.21%

Diluted EPS (TTM)

-1.82

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202455.0M000
20231.6M2.3M9.2M28.1M
202201.9M1.9M0
202117.3M12.3M7.3M2.3M
202055.0M47.6M33.3M22.3M
201986.4M74.7M69.1M59.2M
2018154.4M136.6M116.7M103.3M
2017166.2M175.1M182.7M173.6M
2016176.6M166.2M150.9M149.9M
201554.5M94.0M133.6M173.1M
20146.9M9.6M12.3M15.0M
20136.7M5.9M5.0M4.2M
201226.3M20.1M13.8M7.5M
201135.6M34.1M032.6M
201000037.1M
200900042.1M

Tracking the Latest Insider Buys and Sells of Avadel Pharmaceuticals PLC

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 16, 2024
mchugh thomas s
bought
29,000
14.5
2,000
chief financial officer
Dec 28, 2023
mccamish mark anthony
sold
-1,089,750
14.53
-75,000
-
Aug 14, 2023
mchugh thomas s
bought
28,900
14.45
2,000
chief financial officer
Aug 11, 2023
mccamish mark anthony
sold
-432,614
14.9306
-28,975
-
Aug 10, 2023
divis gregory j
bought
131,997
13.1997
10,000
chief executive officer
Aug 10, 2023
glass geoffrey michael
bought
187,600
13.4
14,000
-
May 18, 2023
ende eric j
bought
181,100
13.9308
13,000
-
May 09, 2023
palczuk linda
bought
36,900
14.76
2,500
-
Dec 23, 2022
palczuk linda
bought
14,405
7.2025
2,000
-
Nov 29, 2022
mchugh thomas s
bought
39,000
7.8
5,000
chief financial officer

1–10 of 46

Which funds bought or sold AVDL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 16, 2024
ORG Partners LLC
sold off
-100
-2,149
-
-%
Jul 12, 2024
Diversify Advisory Services, LLC
sold off
-100
-539,168
-
-%
Jul 12, 2024
Edge Wealth Management LLC
sold off
-100
-675,600
-
-%
Jul 12, 2024
Blue Zone Wealth Advisors, LLC
sold off
-100
-304,020
-
-%
Jul 12, 2024
BALDWIN BROTHERS LLC/MA
sold off
-100
-8,445
-
-%
Jul 11, 2024
SALEM INVESTMENT COUNSELORS INC
sold off
-100
-7,601
-
-%
Jul 10, 2024
CWM, LLC
unchanged
-
-1,000
1,000
-%
Jul 02, 2024
GAMMA Investing LLC
sold off
-100
-17,971
-
-%
May 24, 2024
Cetera Investment Advisers
new
-
1,925,090
1,925,090
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
sold off
-100
-146,000
-
-%

1–10 of 42

Are Funds Buying or Selling AVDL?

Are funds buying AVDL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AVDL
No. of Funds

Unveiling Avadel Pharmaceuticals PLC's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
rtw investments, lp
9.99%
9,196,186
SC 13G/A
Feb 13, 2024
polar capital holdings plc
7.51%
6,751,782
SC 13G
Feb 13, 2024
janus henderson group plc
12.4%
11,125,330
SC 13G/A
Feb 13, 2024
gendell jeffrey l
3.94%
3,539,782
SC 13G/A
Feb 12, 2024
kotler kevin
4.1%
3,716,242
SC 13G/A
Aug 10, 2023
janus henderson group plc
12.3%
9,443,642
SC 13G
Mar 09, 2023
kotler kevin
5.1%
3,122,100
SC 13G
Feb 14, 2023
gendell jeffrey l
5.33%
3,294,817
SC 13G/A
Feb 14, 2023
rtw investments, lp
9.3%
5,741,939
SC 13G/A
Feb 14, 2023
vivo opportunity, llc
3.6%
2,251,663
SC 13G/A

Recent SEC filings of Avadel Pharmaceuticals PLC

View All Filings
Date Filed Form Type Document
Jun 27, 2024
8-K
Current Report
Jun 18, 2024
DEFA14A
DEFA14A
Jun 18, 2024
DEF 14A
DEF 14A
Jun 18, 2024
ARS
ARS
May 21, 2024
8-K
Current Report
May 21, 2024
4
Insider Trading
May 21, 2024
3
Insider Trading
May 17, 2024
S-8
Employee Benefits Plan
May 08, 2024
8-K
Current Report
May 08, 2024
8-K
Current Report

Peers (Alternatives to Avadel Pharmaceuticals PLC)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
374.1B
85.6B
6.72% -2.08%
9.72
4.37
5.68% 202.39%
315.0B
61.4B
-2.82% 17.39%
136.61
5.13
6.11% -82.30%
177.5B
29.5B
8.12% 42.57%
47.16
6.01
12.76% -52.47%
168.3B
35.0B
8.35% -18.50%
144.83
4.8
-26.40% -92.03%
91.6B
27.4B
16.41% -6.90%
189.03
3.34
1.51% -91.32%
18.3B
16.0B
-3.94% 90.89%
-37.11
1.15
7.23% 71.10%
MID-CAP
4.2B
1.7B
1.02% -22.25%
9.6
2.42
54.01% 364.56%
3.8B
4.6B
8.22% -19.25%
-489.51
0.83
-0.06% 94.55%
2.7B
9.0B
14.06% -20.56%
-5.95
0.3
10.01% -27.45%
1.9B
676.2M
-0.80% -36.26%
12.57
2.87
30.38% 66.04%
SMALL-CAP
1.4B
743.2M
7.69% 2.82%
-4
1.9
24.65% 80.36%
20.9M
1.3M
-2.69% -55.31%
-2.82
16.12
-98.14% -104.71%
14.6M
89.6M
10.26% -18.10%
-1.03
0.19
287.27% -129.41%
9.9M
21.5M
323.53% -53.25%
-1.28
0.46
66.16% 61.84%
322.9K
115.7M
-61.54% -97.23%
0
0
-2.22% -352.48%

Avadel Pharmaceuticals PLC News

Latest updates
Defense World28 hours ago
Yahoo News Australia15 Jul 202412:31 am
Seeking Alpha16 Jun 202407:00 am

Avadel Pharmaceuticals PLC Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q32022Q22021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue40.4%27,178,00019,356,5007,014,0001,496,000193,000448,000192,000812,000489,000432,000216,000--10,091,00012,243,00010,995,00014,229,00017,554,00016,437,00020,920,00019,826,000
Gross Profit36.8%25,656,00018,760,0006,897,0001,460,000-----------------
Costs and Expenses---42,007,00051,001,00028,298,00016,960,00029,937,00023,136,00025,663,00021,936,00014,811,00014,260,00013,697,000-30,178,00018,740,00018,342,00018,376,00022,005,00024,604,00096,341,00033,921,000
Operating Expenses-51,691,000---28,298,000----------------
  S&GA Expenses17.7%48,623,00041,301,00039,158,00046,778,00024,468,00014,096,00021,804,00021,026,00021,283,00015,174,00011,012,0008,974,0008,423,0007,095,0007,913,0007,663,0005,316,0006,758,00010,446,00023,200,00024,829,000
  R&D Expenses30.1%3,068,0002,359,0002,849,0004,223,0003,830,0002,933,0004,541,0002,110,0004,380,0006,762,0003,852,0005,286,0005,569,0004,057,0005,530,0007,757,0007,539,00010,292,0007,329,0006,086,00011,402,000
EBITDA Margin50.1%-2.76-5.53-15.97-55.22-58.75-49.65-54.67-35.16-9.61-4.760.14----------
Interest Expenses168.4%2,592,000-3,789,0001,978,0002,295,0003,259,0003,564,0003,506,0004,154,0001,929,0001,930,0001,929,0003,308,0003,259,0003,237,0003,190,0003,190,0003,125,0003,106,0003,062,0003,045,0003,000,000
Income Taxes193.0%93,000-100,00089,00090,000-580,00070,00030,193,000-4,343,000-5,101,000-3,765,000-2,607,000-2,852,000-5,040,0005,292,000-9,510,000-8,997,0002,234,0001,781,000-374,000-14,533,000-691,000
Earnings Before Taxes5.7%-27,249,000-28,886,000-36,185,000-64,342,000-31,364,000-20,076,000-33,251,000-26,644,000-27,103,000-23,346,000-16,052,000-14,130,000-16,743,00036,166,000-10,375,000-11,736,000-6,630,000-6,824,000-13,392,000-78,392,000-16,462,000
EBT Margin50.3%-2.85-5.73-17.40-61.46-68.12-57.04-61.17-39.75-10.98-5.70-0.62----------
Net Income5.0%-27,342,000-28,786,000-36,274,000-64,432,000-30,784,000-20,146,000-63,444,000-22,301,000-22,002,000-19,581,000-13,445,000-11,278,000-11,703,00030,874,000-865,000-2,739,000-8,864,000-8,605,000-13,018,000-63,859,000-15,771,000
Net Income Margin50.1%-2.85-5.71-17.37-61.32-86.22-68.17-69.70-33.00-9.03-4.54-0.32----------
Free Cashflow-6.0%-29,704,000-28,029,000-38,226,000-32,023,000-30,233,000-7,519,000-14,090,000-22,506,000-21,238,000-10,153,000-23,439,000----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets1.9%168165203201141133146158221247264283293312328341208151156166174
  Current Assets1.4%13613417217110910111312616119220623124226328227713182.0089.0097.00102
    Cash Equivalents14.8%36.0031.0052.0050.0083.0074.0061.0054.0061.0051.0058.0067.0059.0072.0083.0010274.0010.0013.0017.0010.00
  Inventory14.9%12.0010.005.001.00------------4.004.002.003.004.00
  Net PPE-10.1%1.001.001.001.001.001.001.000.000.000.000.000.000.000.000.000.000.001.001.001.002.00
  Goodwill0%17.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0018.0018.0018.0018.0018.00
Liabilities16.3%90.0077.0093.0058.00179154158161166169165164156149156159176181183183183
  Current Liabilities29.7%48.0037.0054.0052.0079.0056.0042.0046.0044.0021.0018.0016.009.0015.0023.0027.0032.0036.0032.0034.0031.00
  Long Term Debt-----93.0092.00110108117142142142141128127125123122120119117
    LT Debt, Current---21.0021.0021.0038.0026.0026.0026.00---------0.000.000.00
    LT Debt, Non Current-----93.0092.00110108117142142142141128127125123122120119117
Shareholder's Equity-10.7%78.0088.00110143-38.17-21.14--55.0078.0099.0011913716217118232.00----
  Retained Earnings-3.7%-772-745-716-680-616-585-557-537-474-447-425-403-383-384-372-361-392-391-388-379-371
  Additional Paid-In Capital2.2%874855852849603590573560554549547544542567565615497434434434434
Shares Outstanding7.0%96.0090.0089.0089.0064.0063.0059.0059.0059.0059.0059.0058.00---------
Float----1,459---142---390---467---98.00-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-6.0%-29,704-28,029-38,226-32,023-30,233-15,366-6,803-14,090-34,045-22,506-21,238-10,153-23,413-19,125-10,192-7,781-11,636-8,253-7,419-1,447-21,206
  Share Based Compensation53.2%5,3893,5183,1277,6441,5221,9271,9236582,5052,7842,3592,0011,7281,294194769742342-22955.00351
Cashflow From Investing-23.4%21,38727,9289,821-92,9085,06622,8752,52412,04842,25115,32012,29418,12411,1917,241-9,300-80,88813,2265,1703,2178,94621,390
Cashflow From Financing162.5%13,190-21,11130,46091,54434,4426,62210,715-4,8032,009-114-149183-16.00117,30662,210-41.00-41.00-37.0092.00
  Buy Backs----------------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

AVDL Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Statement of Comprehensive Income [Abstract]  
Net loss$ (27,342)$ (30,784)
Other comprehensive (loss) income, net of tax:  
Foreign currency translation (loss) income(236)175
Net other comprehensive (loss) income, net of income tax expense of $0 and $0, respectively(353)140
Total other comprehensive (loss) income, net of tax(589)315
Total comprehensive loss$ (27,931)$ (30,469)

AVDL Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 35,794$ 31,167
Marketable securities52,99573,944
Accounts receivable, net22,69212,103
Inventories11,92810,380
Research and development tax credit receivable1,2931,322
Prepaid expenses and other current assets11,3335,286
Total current assets136,035134,202
Property and equipment, net526585
Operating lease right-of-use assets2,3742,591
Goodwill16,83616,836
Research and development tax credit receivable360332
Other non-current assets11,76810,152
Total assets167,899164,698
Current liabilities:  
Current portion of operating lease liability953934
Accounts payable18,96111,433
Accrued expenses27,64224,227
Other current liabilities252261
Total current liabilities47,80836,855
Long-term operating lease liability1,4491,690
Royalty financing obligation34,33332,760
Other non-current liabilities5,9255,654
Total liabilities89,51576,959
Shareholders’ equity:  
Preferred shares, nominal value of $0.01 per share; $50,000 shares authorized; zero issued and outstanding at March 31, 2024 and $5,194 issued and outstanding at December 31, 2023052
Ordinary shares, nominal value of $0.01 per share; $500,000 shares authorized; $96,097 issued and outstanding at March 31, 2024 and $89,825 issued and outstanding at December 31, 2023960898
Additional paid-in capital874,018855,452
Accumulated deficit(772,838)(745,496)
Accumulated other comprehensive loss(23,756)(23,167)
Total shareholders’ equity78,38487,739
Total liabilities and shareholders’ equity$ 167,899$ 164,698
AVDL
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
 CEO
 WEBSITEavadel.com
 INDUSTRYPharmaceuticals
 EMPLOYEES41

Avadel Pharmaceuticals PLC Frequently Asked Questions


What is the ticker symbol for Avadel Pharmaceuticals PLC? What does AVDL stand for in stocks?

AVDL is the stock ticker symbol of Avadel Pharmaceuticals PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Avadel Pharmaceuticals PLC (AVDL)?

As of Thu Jul 18 2024, market cap of Avadel Pharmaceuticals PLC is 1.53 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVDL stock?

You can check AVDL's fair value in chart for subscribers.

What is the fair value of AVDL stock?

You can check AVDL's fair value in chart for subscribers. The fair value of Avadel Pharmaceuticals PLC is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Avadel Pharmaceuticals PLC is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AVDL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Avadel Pharmaceuticals PLC a good stock to buy?

The fair value guage provides a quick view whether AVDL is over valued or under valued. Whether Avadel Pharmaceuticals PLC is cheap or expensive depends on the assumptions which impact Avadel Pharmaceuticals PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVDL.

What is Avadel Pharmaceuticals PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 18 2024, AVDL's PE ratio (Price to Earnings) is -9.77 and Price to Sales (PS) ratio is 27.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVDL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Avadel Pharmaceuticals PLC's stock?

In the past 10 years, Avadel Pharmaceuticals PLC has provided 0.016 (multiply by 100 for percentage) rate of return.